ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

NHS England · award, contract

Tender information last checkedLast checked 5 Oct 2026, 05:53.

Opportunity overview

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Awarded to

Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.

The Christie NHS Foundation Trust

Match pending…
Contract value
£11.9m
Awarded
Not supplied
Contract signed
16 Dec 2025
Award ID
003869-2026-11
Status
active
Location
Manchester, UKD, M204BX, United Kingdom

Barts Health NHS Trust

No match
Contract value
£11.9m
Awarded
Not supplied
Contract signed
16 Dec 2025
Award ID
003869-2026-3
Status
active
Location
London, UKI, E1 2ES, United Kingdom

Oxford University Hospitals NHS FT

No match
Contract value
£11.9m
Awarded
Not supplied
Contract signed
16 Dec 2025
Award ID
003869-2026-6
Status
active
Location
Oxford, UKJ, OX3 9DU, United Kingdom

University Hospitals Southampton

No match
Contract value
£11.9m
Awarded
Not supplied
Contract signed
16 Dec 2025
Award ID
003869-2026-7
Status
active
Location
Southampton, UKJ, SO16 6YD, United Kingdom

Classification

  • CPV85100000 — Health services

Lots

  • Lot 1 - LondonValue not stated
  • Lot 2 - East of EnglandValue not stated
  • Lot 3: South EastValue not stated
  • Lot 4: South WestValue not stated
  • Lot 5: MidlandsValue not stated
  • Lot 6: North East & YorkshireValue not stated
  • Lot 7: North WestValue not stated

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
ocds-h6vhtk-0595dd
Status
complete
Main Procurement Category
services
Procurement Method
open
Procurement Method Details
Open procedure

Legal basis

Id
32014L0024
Scheme
CELEX

Classification

Scheme
CPV
Id
85100000
Description
Health services

Covered By

GPA

Lots and requirements

Entry 1
Id
1
Title
Lot 1 - London
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London. <br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 2
Id
2
Title
Lot 2 - East of England
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 3
Id
3
Title
Lot 3: South East
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.<br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 4
Id
4
Title
Lot 4: South West
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 5
Id
5
Title
Lot 5: Midlands
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 6
Id
6
Title
Lot 6: North East & Yorkshire
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.<br/><br/>The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
Entry 7
Id
7
Title
Lot 7: North West
Description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.<br/><br/>The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
Has Options
Yes
Status
cancelled

Award criteria

Criteria

Criterion 1
Name
Quality & innovation
Type
quality
Description
50
Criterion 2
Name
Value
Type
quality
Description
2
Criterion 3
Name
Integration, Collaboration & Service Sustainability
Type
quality
Description
21
Criterion 4
Name
Improving Access, Reducing Health Inequalities and Facilitating Choice
Type
quality
Description
17
Criterion 5
Name
Social Value
Type
quality
Description
10
Criterion 6
Name
Not Applicable
Type
cost
Description
0

Options

Description
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Items and delivery

Item 1
Id
1
Related Lot
1

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKI
Item 2
Id
2
Related Lot
2

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKH
Item 3
Id
3
Related Lot
3

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKJ
Item 4
Id
4
Related Lot
4

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKK
Item 5
Id
5
Related Lot
5

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKF
Entry 2
Region
UKG
Item 6
Id
6
Related Lot
6

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKC
Entry 2
Region
UKE
Item 7
Id
7
Related Lot
7

Additional Classifications

Entry 1
Scheme
CPV
Id
85100000
Description
Health services

Delivery locations

Entry 1
Region
UKD

Buyer, suppliers and contacts

Organisation 1
Name
NHS England
Id
GB-FTS-130973

Identifier

Legal Name
NHS England

Address

Street Address
Wellington House, 133-135 Waterloo Rd
Locality
London
Region
UKJ1
Postal Code
SE1 8UG
Country Name
United Kingdom

Contact

Name
Jessica Gaucher-Thompson

Roles

buyer

Details

Classifications

Entry 1
Scheme
TED_CA_TYPE
Id
BODY_PUBLIC
Description
Body governed by public law
Entry 2
Scheme
COFOG
Id
07
Description
Health
Organisation 2
Name
University College London Hospitals NHS Foundation Trust
Id
GB-FTS-171595

Identifier

Legal Name
University College London Hospitals NHS Foundation Trust

Address

Locality
London
Region
UKI
Postal Code
NW1 2PG
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 3
Name
Guy's and St Thomas' NHS Foundation Trust
Id
GB-FTS-135891

Identifier

Legal Name
Guy's and St Thomas' NHS Foundation Trust

Address

Locality
London
Region
UKI
Postal Code
SE1 9RT
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 4
Name
Barts Health NHS Trust
Id
GB-FTS-171596

Identifier

Legal Name
Barts Health NHS Trust

Address

Locality
London
Region
UKI
Postal Code
E1 2ES
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 5
Name
The Royal Marsden NHS Foundation Trust
Id
GB-FTS-171597

Identifier

Legal Name
The Royal Marsden NHS Foundation Trust

Address

Locality
London
Region
UKI
Postal Code
SW3 6JJ
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 6
Name
Cambridge University Hospitals NHS Foundation Trust
Id
GB-FTS-10778

Identifier

Legal Name
Cambridge University Hospitals NHS Foundation Trust

Address

Locality
Cambridge
Region
UKH
Postal Code
CB2 0QQ
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 7
Name
Oxford University Hospitals NHS FT
Id
GB-FTS-171598

Identifier

Legal Name
Oxford University Hospitals NHS FT

Address

Locality
Oxford
Region
UKJ
Postal Code
OX3 9DU
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 8
Name
University Hospitals Southampton
Id
GB-FTS-171599

Identifier

Legal Name
University Hospitals Southampton

Address

Locality
Southampton
Region
UKJ
Postal Code
SO16 6YD
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 9
Name
University Hospitals Bristol and Weston NHS Foundation Trust
Id
GB-FTS-72289

Identifier

Legal Name
University Hospitals Bristol and Weston NHS Foundation Trust

Address

Locality
Bristol
Region
UKK
Postal Code
BS1 3NU
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 10
Name
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
Id
GB-FTS-171600

Identifier

Legal Name
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

Address

Locality
Leicester
Region
UKF
Postal Code
LE1 5WW
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 11
Name
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Id
GB-FTS-171601

Identifier

Legal Name
The Newcastle upon Tyne Hospitals NHS Foundation Trust

Address

Locality
Newcastle upon Tyne
Region
UKC
Postal Code
NE1 4LP
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 12
Name
The Christie NHS Foundation Trust
Id
GB-FTS-171602

Identifier

Legal Name
The Christie NHS Foundation Trust

Address

Locality
Manchester
Region
UKD
Postal Code
M204BX
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 13
Name
THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Id
GB-FTS-171603

Identifier

Legal Name
THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

Address

Locality
Wirral
Region
UKD
Postal Code
CH634JY
Country Name
United Kingdom

Roles

supplier

Details

Scale
large
Organisation 14
Name
NHS Arden and Greater East Midlands Commissioning Support Unit
Id
GB-FTS-141301

Identifier

Legal Name
NHS Arden and Greater East Midlands Commissioning Support Unit

Address

Street Address
Cardinal Square, 10 Nottingham Road
Locality
Derby
Postal Code
DE1 3QT
Country Name
United Kingdom

Roles

reviewBody

Details

Award information

Award 1
Id
003869-2026-1
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171595
Name
University College London Hospitals NHS Foundation Trust
Award 2
Id
003869-2026-2
Status
active

Suppliers

Supplier 1
Id
GB-FTS-135891
Name
Guy's and St Thomas' NHS Foundation Trust
Award 3
Id
003869-2026-3
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171596
Name
Barts Health NHS Trust
Award 4
Id
003869-2026-4
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171597
Name
The Royal Marsden NHS Foundation Trust
Award 5
Id
003869-2026-5
Status
active

Suppliers

Supplier 1
Id
GB-FTS-10778
Name
Cambridge University Hospitals NHS Foundation Trust
Award 6
Id
003869-2026-6
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171598
Name
Oxford University Hospitals NHS FT
Award 7
Id
003869-2026-7
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171599
Name
University Hospitals Southampton
Award 8
Id
003869-2026-8
Status
active

Suppliers

Supplier 1
Id
GB-FTS-72289
Name
University Hospitals Bristol and Weston NHS Foundation Trust
Award 9
Id
003869-2026-9
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171600
Name
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
Award 10
Id
003869-2026-10
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171601
Name
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Award 11
Id
003869-2026-11
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171602
Name
The Christie NHS Foundation Trust
Award 12
Id
003869-2026-12
Status
active

Suppliers

Supplier 1
Id
GB-FTS-171603
Name
THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

Contracts and changes

Entry 1
Id
003869-2026-1
Award ID
003869-2026-1
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 2
Id
003869-2026-2
Award ID
003869-2026-2
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 3
Id
003869-2026-3
Award ID
003869-2026-3
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 4
Id
003869-2026-4
Award ID
003869-2026-4
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 5
Id
003869-2026-5
Award ID
003869-2026-5
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 6
Id
003869-2026-6
Award ID
003869-2026-6
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 7
Id
003869-2026-7
Award ID
003869-2026-7
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 8
Id
003869-2026-8
Award ID
003869-2026-8
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 9
Id
003869-2026-9
Award ID
003869-2026-9
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 10
Id
003869-2026-10
Award ID
003869-2026-10
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 11
Id
003869-2026-11
Award ID
003869-2026-11
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP
Entry 12
Id
003869-2026-12
Award ID
003869-2026-12
Status
active
Date Signed
16 Dec 2025, 00:00

Value

Amount
11,876,000
Currency
GBP

Recorded locations

  • Buyer location · London · UKJ1 · SE1 8UG · United Kingdom
  • Delivery location · UKC
  • Delivery location · UKD
  • Delivery location · UKE
  • Delivery location · UKF
  • Delivery location · UKG
  • Delivery location · UKH
  • Delivery location · UKI
  • Delivery location · UKJ
  • Delivery location · UKK

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. 003869-2026award, contract ·